Hexima is conducting a phase IIb clinical trial of its lead antifungal molecule, pezadeftide (previously HXP124), as a potential topical treatment for fungal nail infections (onychomycosis).
Investor Webinar Recording
Latest NailMail Newsletter
Thanks to those who joined our Investor Review Webinar held on 8 Sept 2021. A full recording is now available by clicking the link below.